SOURCE: Protherics PLC

April 10, 2007 13:09 ET

Protherics PLC announces Blocklisting Interim Review

Cheshire, UK -- (MARKET WIRE) -- April 10, 2007 --

                                Protherics PLC

                         6 monthly Block Listing Return
                     Approved Executive Share Option Scheme


London, UK; Brentwood, TN, US: 10 April 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that the following 6 monthly block listing return in
respect of the Company's Approved Executive Share Option Scheme has been lodged
with the FSA today, in accordance with Listing Rule 3.5.6.



Name of applicant:                                         Protherics PLC

Name of scheme:                                            Protherics PLC Approved Executive Share Option Scheme

Period of return:                           From:          9 October 2006         To:        8 April 2007

Balance under scheme from previous return:                 356,924

The amount by which the block scheme has been increased,   Nil
if the scheme has been increased since the date of the
last return:

Number of securities issued/allotted under scheme during   21,625
period:

Balance under scheme not yet issued/allotted at end of     335,299
period

Number and class of securities originally listed and the   387,712 Ordinary Shares (date of admission: 8 April 2005)
date of admission

Total number of securities in issue at the end of the      339,169,625
period
                                                           



                                    |  Ends  |



For further information please contact:


Protherics

Nick Staples, Director of Corporate Affairs               +44 (0) 7919  480510

Julie Vickers, Company Secretary                          +44 (0)1928 518000


Financial Dynamics - press enquiries

London: Ben Atwell, Anna Keeble                           +44 (0) 20 7831 3113

New York: John Capodanno, Jonathan Birt                   +1 212 850 5600


Or visit  www.protherics.com





                      This information is provided by RNS
            The company news service from the London Stock Exchange